Predicting Outcome after Acute Basilar Artery Occlusion Based on Admission CharacteristicsAuthor Response:
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Editors' Note: In reference to “Predicting outcome after acute basilar artery occlusion based on admission characteristics” by Drs. Greving et al., Drs. He and Li argue against a 9-hour treatment window for intra-arterial therapy, against the use of recanalization as a predictor of outcome, and for the development of prediction models for different treatment strategies. The authors respond. Drs. Li et al. comment on the new American Academy of Neurology guideline on IV immunoglobulin (IVIg) for neuromuscular disorders, pointing out where evidence is still lacking on the use of IVIg in myasthenia gravis. Robert C. Griggs, MD, and Megan Alcauskas, MD
Greving et al.1 composed a prognostic model to predict outcome of acute basilar artery occlusion (BAO). There are some problems to be resolved before utilization.
First, according to the results of the Basilar Artery International Cooperation Study (BASICS), all 31 cases with a severe deficit and 16/22 cases with a mild to moderate deficit had a poor outcome with intra-arterial therapy (IAT) when the time to treatment exceeded 9 hours.2 Should we recommend 9 hours as the time window for treating acute BAO with IAT?
Second, the BASICS results showed recanalization protected against poor outcome in IAT and IV thrombolysis (IVT) groups.2 Recanalization is an extremely important factor but is not used as a predictor in these 3 models.1
Third, did those cases with or without occlusion and presence of prodromal minor stroke get aggressive medical therapy? If they did, aggressive medical therapy might protect more cases from stroke or occlusion and prodromal minor stroke would not only be a predictive factor but also a protective factor.3
Finally, different hospitals or centers have frequently used treatment strategies for various conditions, especially in developing countries. For these reasons, different prediction models for different treatment strategies will be necessary.
Author Response:
We appreciate the interest of Drs. He and Li and response to our prognostic article.1 We agree that recanalization is an important predictor of outcome. However, our focus was on those factors available at the time of admission.
Our prediction model is meant to be used prior to the initiation of therapy. The results from the BASICS registry showed that type of treatment had no significant influence on outcome at 1 month.2 Our data do not enable any recommendations to be made with regard to the choice between IVT vs IAT in any time window.
We agree that the design of a prediction model for different treatment strategies is a high priority, but should await the results from the recently initiated BASICS trial.4 In the meantime, we recommend treating patients with BAO with IVT. Additional IAT could be considered within a time window of 6 hours from the onset of a severe deficit. Little gain is expected in the 6- to 9-hour time window, but IAT could be considered in selected cases. The 28% good outcome rate among IA-treated patients with a mild to moderate deficit suggests there is still potential gain of IAT beyond the 9-hour time window. Primary IAT should only be considered in patients with a contraindication for IVT.
References
- 1.↵
- Greving JP,
- Schonewille WJ,
- Wijman CA,
- Michel P,
- Kappelle LJ,
- Algra A.
- 2.↵
- 3.↵
- 4.↵
Basilar Artery International Cooperation Study (BASICS) trial. Available at: http://basicstrial.com/. Accessed August 11, 2012.
- Copyright © 2012 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Alert Me
Recommended articles
-
Five New Things
Myasthenia gravisFive new thingsJeffrey M. Statland, Emma Ciafaloni et al.Neurology: Clinical Practice, April 15, 2013 -
Eye on Practice
An analysis of AAN′s evidence-based guideline for IVIg use in neurologic disordersProvider impact and payer perspectivesSaty Satya-Murti, Katie M. Shepard, Joel M. Kaufman et al.Neurology: Clinical Practice, June 11, 2012 -
Articles
Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitalsA. Alshekhlee, J. D. Miles, B. Katirji et al.Neurology, May 04, 2009 -
Special Article
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosisReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of NeurologyAlexander Rae-Grant, Gregory S. Day, Ruth Ann Marrie et al.Neurology, April 23, 2018